Scholarlink

<p>High-grade gliomas are one of the most lethal cancers and the leading cause of cancer-related mortality in children. Standard treatment typically involves resection, chemotherapy and radiation, yet offer limited improvement in survival rates. Targeted therapies are emerging to show effect in solid tumors harboring tyrosine-kinase activating fusion genes. Here, we present a thorough characterization of an epithelioid glioblastoma in a six-year-old patient, with four relapses and a variety of different treatment strategies. We identified a rare <i>TRIM24::NTRK2</i> fusion in the primary tumor, which enabled a targeted TRK-inhibitor treatment. Our findings show that the <i>TRIM24::NTRK2</i> fusion initially had oncogenic abilities, but this became less imperative as the tumor evolved. A general drug resistance to TRK-inhibition was documented. This study addresses the complex and adaptive nature of pediatric epithelioid glioblastomas and highlights the need for continued molecular profiling from relapses and various tumor regions to enable multitarget treatment approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive characterization and targeted treatment of a pediatric epithelioid glioblastoma with a rare TRIM24-NTRK2 fusion

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月2日

查看全文
  • Simon Keane,
  • Ida Sjöberg,
  • Lily Deland,
  • Angelica Lindlöf,
  • Thomas Olsson Bontell,
  • Teresia Kling,
  • Malin Blomstrand,
  • Henrik Fagman,
  • Jonas A. Nilsson,
  • Daniel Nilsson,
  • Magnus Sabel,
  • Helena Carén,
  • Frida Abel

摘要

High-grade gliomas are one of the most lethal cancers and the leading cause of cancer-related mortality in children. Standard treatment typically involves resection, chemotherapy and radiation, yet offer limited improvement in survival rates. Targeted therapies are emerging to show effect in solid tumors harboring tyrosine-kinase activating fusion genes. Here, we present a thorough characterization of an epithelioid glioblastoma in a six-year-old patient, with four relapses and a variety of different treatment strategies. We identified a rare TRIM24::NTRK2 fusion in the primary tumor, which enabled a targeted TRK-inhibitor treatment. Our findings show that the TRIM24::NTRK2 fusion initially had oncogenic abilities, but this became less imperative as the tumor evolved. A general drug resistance to TRK-inhibition was documented. This study addresses the complex and adaptive nature of pediatric epithelioid glioblastomas and highlights the need for continued molecular profiling from relapses and various tumor regions to enable multitarget treatment approaches.